Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Construction of a new, state-of-the-art scientific and innovation center in the Amgen global seat in thousands of oaks, California.
Courtage: Amgen
Amogen Tuesday said they would spend more than $ 600 million for the construction of a new research and development facility in their seat in thousands of oaks, California, no later than in a series New American investments by the pharmaceutical industry.
Drugs tried to insert their presence in the US as a president Donald Trump threatens to clamp in industry Tariffs on pharmaceous imported into the ground. Trump said it will encourage companies to re-perform production at the time when domestic drug production has given dramatically in the past decade.
In relation, Amgen said the construction of the facility would begin in the third quarter of this year and will create hundreds of American jobs.
Mateau, the facility is not a manufacturing factory, but will allow researchers, engineers and scientists to cooperate on finding drugs for the next generation for patients with “most serious diseases”, according to society. Amgen said that the construction characteristics of “advanced automation and digital possibilities”, which will give scientists the necessary tools for this research and development.
“In Amgen, we continue to invest in the future of American science and innovation,” said General Manager Bob Braday in release. “The center will strengthen our scientists with tools and collaborative environments they need to form the next era of scientific discoveries and pre-medications that improve people’s health.”
Amgen said that from the adoption of tax reduction and job activities, invested almost $ 5 billion into direct American capital expenditures. The company announced a spread of $ 900 million with Ohio Biothech in April. The pharmacy announced in December Spend a billion dollars Build another drug addict in Holly Springs, North Carolina.
These investments come after US food and drug administration in August started the program What aims to facilitate the introduction of new drug production facilities in the United States, a white house estimate, can currently last for five to 10 years to build new production capacity for pharmaceutical products, which is Previously named “unacceptable From the point of view of national security. “
